Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2023-2029

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2023-2029

Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
LPI (LP Information)' newest research report, the “Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Forecast” looks at past sales and reviews total world Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) sales in 2022, providing a comprehensive analysis by region and market sector of projected Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) sales for 2023 through 2029. With Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry.
This Insight Report provides a comprehensive analysis of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size is projected to grow from US$ 14070 million in 2022 to US$ 57240 million in 2029; it is expected to grow at a CAGR of 22.2% from 2023 to 2029.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
This report presents a comprehensive overview, market shares, and growth opportunities of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
CellSearch
Others
Segmentation by application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems

Please note: The report will take approximately 2 business days to prepare and deliver.